Table 1

Baseline characteristics of the AS study population

Total

IFX

ETA

ADA


Number of patients

220

32

137

51

Age (yrs)

42.9 ± 11.9

45.8 ± 10.1

41.9 ± 11.6

43.7 ± 13.3

Gender (male) (n, %)

152 (69)

20 (63)

96 (70)

36 (71)

Duration of symptoms (yrs)

15 (1 to 53)

21 (2 to 49)

15 (1 to 47)

11 (1 to 53)

Time since diagnosis (yrs)

7 (0 to 45)

16 (0 to 35)*

7 (0 to 44)

6 (0 to 45)

HLA-B27+ (n, %)

174 (81)

24 (75)

108 (82)

42 (82)

History of IBD (n, %)

20 (9)

8 (26)†

7 (5)

4 (8)

History of uveitis (n, %)

64 (29)

13 (40)

44 (32)

7 (14)‡

History of psoriasis (n, %)

13 (6)

3 (9)

8 (6)

13 (6)

Peripheral arthritis (n, %)

37 (17)

5 (16)

27 (20)

5 (10)

Current NSAID use (n, %)

158 (72)

24 (75)

102 (75)

32 (63)

Current DMARD use (n, %)

45 (21)

10 (31)

28 (20)

7 (14)

BASDAI (range 0 to 10)

6.1 ± 1.7

6.1 ± 1.4

6.2 ± 1.7

5.9 ± 1.7

ASDAS

3.8 ± 0.8

3.8 ± 0.6

3.8 ± 0.8

3.7 ± 0.9

Physician's GDA (range 0-10)

5 (0 to 9)

5 (0 to 8)

5 (0 to 9)

3 (0 to 9)‡

Patient's GDA (range 0 to 10)

7 (1 to 10)

6 (1 to 9)

7 (1 to 10)

6 (1 to 10)

ESR (mm/h)

21 (2 to 101)

24 (2 to 90)

20 (2 to 101)

23 (2 to 74)

CRP (mg/l)

13 (2 to 99)

15 (2 to 74)

12 (2 to 99)

14 (2 to 92)

BASFI (range 0 to 10)

6.1 (0.3 to 9.7)

6.3 (1.9 to 9.6)

5.9 (0.3 to 9.7)

6.3 (0.4 to 9.5)

Chest expansion (cm)

3.0 (0.5 to 43.0)

2.5 (0.5 to 7.0)

3.0 (0.5 to 22.0)

3.5 (0.0 to 43.0)§

Modified Schober test (cm)

2.9 (0.0 to 7.0)

2.4 (0.5 to 6.0)

2.8 (0.1 to 7.0)

3.2 (0.0 to 5.5)

Occiput to wall distance (cm)

4.9 (0.0 to 34.5)

9.0 (0.0 to 26.0)^

4.5 (0.0 to 34.5)

3.5 (0.0 to 30.0)

Lateral lumbar flexion L (cm)

8.0 (0.0 to 30.0)

7.0 (2.0 to 15.0)

9.0 (0.0 to 30.0)

8.0 (1.0 to 20.5)

Lateral lumbar flexion R (cm)

8.0 (0.0 to 29.0)

8.0 (0.5 to 17.0)

8.0 (0.0 to 29.0)

7.5 (1.0 to 20.0)


Values are mean ± SD or median (range) unless otherwise indicated.

AS, Ankylosing Spondylitis; IFX, infliximab; ETA, etanercept; ADA, adalimumab; HLA-B27+, human leukocyte antigen B27 positive; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; DMARD, disease-modifying antirheumatic drug; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; GDA, global disease activity; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASFI, Bath Ankylosing Spondylitis Functional Index; L, left; R, right.

* P < 0.05 compared to ETA group and P = 0.052 compared to ADA group.

P < 0.05 compared to ETA group and P = 0.050 compared to ADA group.

P < 0.05 compared to IFX and ETA groups.

§ P < 0.05 compared to ETA group.

^ P < 0.05 compared to ETA and ADA groups.

Arends et al. Arthritis Research & Therapy 2011 13:R94   doi:10.1186/ar3369

Open Data